• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

印度钦奈市第二波 COVID-19 感染期间,当前 RT-PCR 阳性个体中之前的 SARS-CoV-2 感染状况。

Previous SARS-CoV-2 Infection Status Among the Current RT-PCR-Positive Individuals Affected During the Second Wave of COVID-19 Infections in Chennai, India.

机构信息

ICMR-National Institute of Epidemiology, Chennai, India.

ICMR-National Institute of Virology, Pune, India.

出版信息

Front Public Health. 2022 Apr 4;10:836454. doi: 10.3389/fpubh.2022.836454. eCollection 2022.

DOI:10.3389/fpubh.2022.836454
PMID:35444976
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9013836/
Abstract

India witnessed a very strong second wave of coronavirus disease 2019 (COVID-19) during March and June 2021. Newly emerging variants of concern can escape immunity and cause reinfection. We tested newly diagnosed COVID-19 cases during the second wave in Chennai, India for the presence of Immunoglobulin G (IgG) antibodies to estimate the extent of re-infection. Of the 902 unvaccinated COVID-19 positive individuals, 53 (26.5%) were reactive for IgG antibodies and non-reactive for Immunogobulin M (IgM) antibodies. Among the 53 IgG-positive individuals, the interval between symptom onset (or last contact with the known case in case of asymptomatic) was <5 days in 29 individuals, ≥5 days in 11 individuals, while 13 asymptomatic individuals did not know their last contact with a positive case. The possible re-infections ranged between 3.2% (95% CI: 2.2-4.5%) and 4.3% (95% CI: 3.4-6.2%). The findings indicate that re-infection was not a major reason of the surge in cases during second wave. The IgG seropositivity among recently diagnosed unvaccinated COVID-19 patients could provide early indications about the extent of re-infections in the area.

摘要

印度在 2021 年 3 月至 6 月期间经历了非常强烈的 2019 年冠状病毒病(COVID-19)第二波疫情。新出现的关注变种可以逃避免疫并导致再次感染。我们在印度钦奈对第二波疫情中的新诊断 COVID-19 病例进行了 IgG 抗体检测,以评估再感染的程度。在 902 名未接种疫苗的 COVID-19 阳性个体中,有 53 名(26.5%)对 IgG 抗体呈反应性,而对免疫球蛋白 M(IgM)抗体呈非反应性。在 53 名 IgG 阳性个体中,29 名个体的症状出现(或在无症状情况下与已知病例的最后接触)之间的间隔<5 天,11 名个体的间隔≥5 天,而 13 名无症状个体不知道他们最后一次接触阳性病例。可能的再感染率在 3.2%(95%CI:2.2-4.5%)和 4.3%(95%CI:3.4-6.2%)之间。研究结果表明,再感染不是第二波疫情病例激增的主要原因。最近诊断为未接种疫苗的 COVID-19 患者中的 IgG 血清阳性率可能为该地区再感染的程度提供早期迹象。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7490/9013836/8928394d0cd2/fpubh-10-836454-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7490/9013836/5bf887849a63/fpubh-10-836454-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7490/9013836/8928394d0cd2/fpubh-10-836454-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7490/9013836/5bf887849a63/fpubh-10-836454-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7490/9013836/8928394d0cd2/fpubh-10-836454-g0002.jpg

相似文献

1
Previous SARS-CoV-2 Infection Status Among the Current RT-PCR-Positive Individuals Affected During the Second Wave of COVID-19 Infections in Chennai, India.印度钦奈市第二波 COVID-19 感染期间,当前 RT-PCR 阳性个体中之前的 SARS-CoV-2 感染状况。
Front Public Health. 2022 Apr 4;10:836454. doi: 10.3389/fpubh.2022.836454. eCollection 2022.
2
High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo.刚果共和国布拉柴维尔的无症状刚果人群中 SARS-CoV-2 IgG/IGM 高血清阳性率。
Int J Infect Dis. 2021 May;106:3-7. doi: 10.1016/j.ijid.2020.12.065. Epub 2020 Dec 25.
3
Evidence of SARS-CoV-2 symptomatic reinfection in four healthcare professionals from the same hospital despite the presence of antibodies.尽管存在抗体,但来自同一家医院的四名医护人员仍出现有症状的 SARS-CoV-2 再感染证据。
Int J Infect Dis. 2022 Apr;117:146-154. doi: 10.1016/j.ijid.2022.01.006. Epub 2022 Jan 10.
4
SARS-CoV-2 re-infection: development of an epidemiological definition from India.SARS-CoV-2 再感染:来自印度的流行病学定义的制定。
Epidemiol Infect. 2021 Mar 26;149:e82. doi: 10.1017/S0950268821000662.
5
Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients.通过快速诊断免疫分析检测 COVID-19 患者的 SARS-CoV-2 特异性抗体。
Virol J. 2021 Mar 9;18(1):52. doi: 10.1186/s12985-021-01530-2.
6
Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection.感染后 13 个月 SARS-CoV-2 特异性抗体的持续存在。
Viruses. 2021 Nov 19;13(11):2313. doi: 10.3390/v13112313.
7
SARS-CoV-2 Seroprevalence Among Healthcare Workers by Workplace Exposure Risk in Kashmir, India.印度克什米尔地区不同工作场所暴露风险的医护人员中 SARS-CoV-2 血清流行率。
J Hosp Med. 2021 May;16(5):274-281. doi: 10.12788/jhm.3609.
8
Results of Serosurveillance and Forecasting the Third Wave of COVID-19 in an Industrial District in India.印度某工业区新冠疫情血清学监测结果及第三波疫情预测
Cureus. 2021 Sep 19;13(9):e18097. doi: 10.7759/cureus.18097. eCollection 2021 Sep.
9
First documented reinfection of SARS-COV-2 in second wave from Pakistan.首次从巴基斯坦第二波疫情中记录到 SARS-COV-2 的再感染。
J Ayub Med Coll Abbottabad. 2020 Oct-Dec;32(Suppl 1)(4):S704-S705.
10
SARS-CoV-2 re-infection risk in Austria.奥地利的 SARS-CoV-2 再感染风险。
Eur J Clin Invest. 2021 Apr;51(4):e13520. doi: 10.1111/eci.13520. Epub 2021 Feb 21.

本文引用的文献

1
COVID-19 testing, timeliness and positivity from ICMR's laboratory surveillance network in India: Profile of 176 million individuals tested and 188 million tests, March 2020 to January 2021.印度 ICMR 实验室监测网络的 COVID-19 检测、及时性和阳性率:2020 年 3 月至 2021 年 1 月对 1.76 亿人进行检测和 1.88 亿次检测的概况。
PLoS One. 2021 Dec 3;16(12):e0260979. doi: 10.1371/journal.pone.0260979. eCollection 2021.
2
India grapples with second wave of COVID-19.印度正在应对第二波新冠疫情。
Lancet Microbe. 2021 Jun;2(6):e238. doi: 10.1016/S2666-5247(21)00123-3. Epub 2021 Jun 2.
3
SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021.
2020 年 12 月至 2021 年 1 月期间印度普通人群和医护人员中的 SARS-CoV-2 血清流行率。
Int J Infect Dis. 2021 Jul;108:145-155. doi: 10.1016/j.ijid.2021.05.040. Epub 2021 May 19.
4
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence.尽管血清阳性率很高,巴西玛瑙斯仍出现新冠病毒的卷土重来。
Lancet. 2021 Feb 6;397(10273):452-455. doi: 10.1016/S0140-6736(21)00183-5. Epub 2021 Jan 27.
5
Isolation and characterization of the new SARS-CoV-2 variant in travellers from the United Kingdom to India: VUI-202012/01 of the B.1.1.7 lineage.从英国旅行者中分离和鉴定到的新型 SARS-CoV-2 变异株:B.1.1.7 谱系的 VUI-202012/01。
J Travel Med. 2021 Feb 23;28(2). doi: 10.1093/jtm/taab009.
6
Antibody response to SARS-CoV-2 infection in humans: A systematic review.人类对 SARS-CoV-2 感染的抗体反应:系统综述。
PLoS One. 2020 Dec 31;15(12):e0244126. doi: 10.1371/journal.pone.0244126. eCollection 2020.
7
Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity.2019冠状病毒病再感染、复发及PCR再阳性的定义。
Clin Microbiol Infect. 2021 Mar;27(3):315-318. doi: 10.1016/j.cmi.2020.11.028. Epub 2020 Dec 5.
8
Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2.评价基于核衣壳蛋白和刺突蛋白的酶联免疫吸附试验检测抗 SARS-CoV-2 抗体。
J Clin Microbiol. 2020 May 26;58(6). doi: 10.1128/JCM.00461-20.
9
MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets.MEGA7:适用于更大数据集的分子进化遗传学分析版本7.0
Mol Biol Evol. 2016 Jul;33(7):1870-4. doi: 10.1093/molbev/msw054. Epub 2016 Mar 22.